The standard treatment for transitional cell carcinoma (a cancer of the bladder, ureter, urethra, or kidney) includes the drugs gemcitabine and cisplatin. In this study, researchers want to know if adding the drug bevacizumab to this regimen can help patients with inoperable or metastatic transitional cell carcinoma live longer.
Bevacizumab is already approved for treating advanced cancers of the colon, brain, kidney (renal cell), and lung, but its use for transitional cell cancers is considered investigational. It inhibits the development of the blood vessels that tumors need to grow and spread by blocking a protein called VEGF.
Patients in this study will be randomly assigned to receive gemcitabine/cisplatin/bevacizumab or gemcitabine/cisplatin/placebo.